Procyon Advisors’s Ionis Pharmaceuticals IONS Stock Holding History

Procyon Advisors’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-3	Closed	–	–	603
2020 Q2	$0	Hold	3	–	–	﹤0.01%	1125
2020 Q1	$0	Hold	3	–	–	﹤0.01%	1073
2019 Q4	$0	Buy	+3	New	+$179	﹤0.01%	1030

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Procyon Advisors's IONS Position: Q3 2020 in Review

Procyon Advisors sold out of Ionis Pharmaceuticals (IONS) in Q3 2020, closing a stake of 3 shares.

Procyon Advisors first reported a position in IONS in Q4 2019 and held it in 3 quarters. The position peaked at $0 in Q2 2020. 367 funds tracked by Wall St. Rank hold IONS as of Q3 2020.

Procyon Advisors reported no remaining Ionis Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
Procyon Advisors sold 3 Ionis Pharmaceuticals shares in Q3 2020.
Procyon Advisors first reported a position in Ionis Pharmaceuticals in Q4 2019 and held it in 3 quarters.
Procyon Advisors's Ionis Pharmaceuticals position peaked at $0 in Q2 2020.
367 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q3 2020.

Based on Procyon Advisors's 13F filing for Q3 2020, filed 22 Oct 2020.